Atomoxetine to Treat Adolescents With Coexisting Alcohol and Other Substance Use Disorder and ADHD

Completed · Phase 2

Conditions studied: Substance Use Disorders, Attention Deficit Hyperactivity Disorder

In brief

The purpose of this study is to compare the effectiveness and safety of atomoxetine in the treatment of adolescents with coexisting alcohol or substance use disorders and Attention Deficit Hyperactivity Disorder (ADHD).

Key facts

Study ID

NCT00029614

Run by

University of Pittsburgh

People needed

24

Starts

2006-05-01

Expected to finish

2007-07-01

Last updated by the study team

2010-04-28

Who can join

Age: 13 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adolescents, ages 13-18
• Meets criteria for alcohol and/or substance use disorder and attention deficit hyperactivity disorder.

You may not qualify if…

• Adolescents who are pregnant.
• Have a history of seizure disorder, other neurological or medical disorder for which medication treatment may present a considerable risk.
• History of pervasive development disorder, schizophrenia or other psychotic disorders, organic mental disorders or eating disorders.
• Currently on other psychotropic medications from which discontinuation would present a significant risk.
• A current episode of major depressive disorder or a diagnosis of bipolar disorder.
• Diagnosis of dependence for any substance other than marijuana.
• Adolescents with a full-scale IQ below 80.

Where it is running

• Western Psychiatric Institute and Clinic — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.